# Rock Immune

Source: https://onco.cc/companies/rock-immune/  
OnCo record `rock-immune` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Rock Immune is a Denver company making immunotoxins: proteins that carry a disabled bacterial toxin straight to cancer cells. Its lead candidate, Rock425, is aimed at cutaneous T-cell lymphoma, a lymphoma of the skin.

## Summary

Rock Immune, Inc. describes itself as an early-stage biopharmaceutical company developing diphtheria toxin-based recombinant immunotoxins for cancer and autoimmune disease, made in a proprietary diphtheria toxin-resistant Pichia pastoris yeast system. Its lead candidate Rock425 is a CCR4-IL2 bispecific immunotoxin for cutaneous T-cell lymphoma, which the company reports was effective in a mouse model. A 2026 National Cancer Institute STTR award funds a bivalent CD47 immunotoxin for T-cell acute lymphoblastic leukaemia.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Rock Immune, Inc.
- HQ: Denver, CO
- Type: biotech
- Website: https://rockimmune.com/

## Notes

- Company website and the NIH RePORTER record read on 4 November 2026. The website also mentions an earlier NCI STTR Fast Track grant of USD 2.4 million awarded in July 2021, not read on RePORTER. Founding year not stated.

## Sources

- Official website: https://rockimmune.com/
- NIH RePORTER: award 1R41CA309908-01: https://reporter.nih.gov/project-details/11310680

## Connected records

- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [CCR4](https://onco.cc/targets/ccr4/), [CD47](https://onco.cc/targets/cd47/)
- drugs: [Rock425](https://onco.cc/drugs/rock425/)

---
JSON: https://onco.cc/api/v1/entities/rock-immune.json